Abstract
An autosomal dominant tumor predisposition syndrome, von Hippel-Lindau disease (VHL) is characterized by the presence of benign and malignant tumors. Hallmark lesions include retinal angiomas, hemangioblastomas of the cerebellum and spinal cord, and renal cell carcinomas. Affected persons may also have angiomatous or cystic lesions of the kidneys, pancreas, and epididymis, as well as adrenal pheochromocytomas. In this article, we discuss the clinical features and diagnostic criteria for this clinically underdiagnosed condition. An update on recent findings regarding the molecular genetics of VHL is provided, including a discussion of the evolving understanding of genotype-phenotype correlations. Understanding the molecular and functional aspects of this condition will lead to the development of strategies for the management and treatment of inherited and sporadic VHL-associated tumors.
MeSH terms
-
Adrenal Gland Neoplasms / diagnosis
-
Adrenal Gland Neoplasms / genetics
-
Central Nervous System Neoplasms / diagnosis
-
Central Nervous System Neoplasms / genetics
-
Diagnosis, Differential
-
Genes, Tumor Suppressor
-
Genetic Testing
-
Genotype
-
Hemangioblastoma / diagnosis
-
Hemangioblastoma / genetics
-
Hemangioma / diagnosis
-
Hemangioma / genetics
-
Humans
-
Kidney Neoplasms / diagnosis
-
Kidney Neoplasms / genetics
-
Ligases*
-
Molecular Biology
-
Neovascularization, Pathologic
-
Phenotype
-
Pheochromocytoma / diagnosis
-
Pheochromocytoma / genetics
-
Proteins / genetics
-
Retinal Neoplasms / diagnosis
-
Retinal Neoplasms / genetics
-
Tumor Suppressor Proteins*
-
Ubiquitin-Protein Ligases*
-
Von Hippel-Lindau Tumor Suppressor Protein
-
von Hippel-Lindau Disease / diagnosis*
-
von Hippel-Lindau Disease / genetics*
Substances
-
Proteins
-
Tumor Suppressor Proteins
-
Ubiquitin-Protein Ligases
-
Von Hippel-Lindau Tumor Suppressor Protein
-
Ligases
-
VHL protein, human